IAS 2009 – Cape Town 19-22 July 2009 - International AIDS Society

What Have We Learned from the DART Trial?

TUSS1

Please enter your email :

Type:

Special Session

Back

Venue:

Session Room 2

Time:

07:00 - 08:30, 21.07.2009

Code:

TUSS1

Chairs:

Elly Katabira, Uganda
Pedro Cahn, Argentina

Webcast provided by International AIDS Society

Presentations in this session:

07:00
TUSS101 Introduction
Presented by Elly Katabira, Uganda

07:05
TUSS102
Powerpoint Design of the DART Trial (Development of Antiretroviral Therapy in Africa) and key substudy results
Presented by Ann Sarah Walker, United Kingdom

07:15
TUSS103
Abstract
Powerpoint Impact of routine laboratory monitoring over 5 years after antiretroviral therapy (ART) initiation on clinical disease progression of HIV-infected African adults: the DART Trial final results
Presented by Peter Mugyenyi, Uganda
P. Mugyenyi¹, S. Walker², J. Hakim³, P. Munderi⁴, D. Gibb², C. Kityo¹, A. Reid³, H. Grosskurth⁴, J. Darbyshire², F. Ssali¹, D. Bray², E. Katabira⁵, A. Babiker², C. Gilks^6,7, on behalf of The DART Trial Team
¹Joint Clinical Research Centre (JCRC), Kampala, Uganda, ²MRC Clinical Trials Unit, London, United Kingdom, ³University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe, ⁴MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda, ⁵Infectious Diseases Institute, Kampala, Uganda, ⁶UNAIDS, New Delhi, India, ⁷Imperial College, London, United Kingdom

07:30
TUSS104
Abstract
Powerpoint Cost effectiveness analysis of routine laboratory or clinically driven strategies for monitoring anti-retroviral therapy in Uganda and Zimbabwe (DART Trial)
Presented by Charles Gilks, United Kingdom
A. Medina Lara¹, J. Kigozi², J. Amurwon³, L. Muchabaiwa⁴, B. Nyanzi Wakholi³, S. Walker⁵, R. Kasirye³, F. Ssali², H. Grosskurth³, A. Babiker⁵, C. Kytyo², P. Munderi³, J. Hakim⁴, P. Mugyenyi², D.M. Gibb⁵, A. Reid⁴, J. Darbyshire⁵, C.F. Gilks⁶, DART Trial Team
¹University of Liverpool, Liverpool, United Kingdom, ²Joint Clinical Research Centre (JCRC), Kampala, Uganda, ³MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda, ⁴University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe, ⁵MRC Clinical Trials Unit, London, United Kingdom, ⁶Imperial College, London, United Kingdom

07:45
TUSS105
Powerpoint What have we learnt from the DART Trial?
Presented by James Hakim, Zimbabwe

08:00
TUSS106 Questions and answers with panel

Powerpoints presentations

Design of the DART Trial (Development of Antiretroviral Therapy in Africa) and key substudy results - Walker

Powerpoint (829 KB)

Impact of routine laboratory monitoring over 5 years after antiretroviral therapy (ART) initiation on clinical disease progression of HIV-infected African adults: the DART Trial final results - Mugyenyi

Powerpoint (2.52 MB)

Cost effectiveness analysis of routine laboratory or clinically driven strategies for monitoring anti-retroviral therapy in Uganda and Zimbabwe (DART Trial) - Gilks

Powerpoint (526 KB)

What have we learnt from the DART Trial? - Hakim

Powerpoint (1.04 MB)

The organizers reserve the right to amend the programme.